Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Double-blind, Randomized, Comparative Study of the Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With With Metastatic Colorectal Cancer (mCRC) With Wild-type RAS as First-line Therapy in Combination With FOLFIRI

NCT07543744 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT07543744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07543744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Double-blind, Randomized, Comparative Study of the Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With With Metastatic Colorectal Cancer (mCRC) With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
Lead sponsor
R-Pharm
Phase
Phase 1
Overall status
Recruiting
Start date
April 17, 2025
Completion date
August 31, 2028
Enrollment
180 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer